Cargando…

The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19

The highly infectious disease COVID-19 is induced by SARS-coronavirus 2 (SARS-CoV-2), which has spread rapidly around the globe and was announced as a pandemic by the World Health Organization (WHO) in March 2020. SARS-CoV-2 binds to the host cell’s angiotensin converting enzyme 2 (ACE2) receptor th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahmad, Iqrar, Pawara, Rahul, Surana, Sanjay, Patel, Harun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498772/ https://www.ncbi.nlm.nih.gov/pubmed/34623536 http://dx.doi.org/10.1007/s41061-021-00353-7

Ejemplares similares

SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study
por: Baby, Krishnaprasad, et al.
Publicado: (2021)

Synthesis, Molecular Modeling Study, and Quantum-Chemical-Based Investigations of Isoindoline-1,3-diones as Antimycobacterial Agents
por: Ahmad, Iqrar, et al.
Publicado: (2022)

ACE2, SARS-CoV-2 und RAAS-Blocker
por: Kintscher, Ulrich, et al.
Publicado: (2021)

Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor
por: Han, Dong P., et al.
Publicado: (2006)

Identification of potential inhibitors of SARS-CoV-2 S protein–ACE2 interaction by in silico drug repurposing
por: Tristán-Flores, Fabiola E, et al.
Publicado: (2021)

ACE2: The Major Cell Entry Receptor for SARS-CoV-2
por: Scialo, Filippo, et al.
Publicado: (2020)

SARS-CoV-2 Entry: At the Crossroads of CD147 and ACE2
por: Fenizia, Claudio, et al.
Publicado: (2021)

SARS-CoV-2 cell entry beyond the ACE2 receptor
por: Alipoor, Shamila D., et al.
Publicado: (2022)

Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles
por: Chen, Catherine Z., et al.
Publicado: (2020)

In silico validation of anti-viral drugs obtained from marine sources as a potential target against SARS-CoV-2 M(pro)
por: Ghosh, Srijit, et al.
Publicado: (2021)

Glycyrrhizin Inhibits SARS-CoV-2 Entry into Cells by Targeting ACE2
por: He, Ming-Feng, et al.
Publicado: (2022)

Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2
por: Qiao, Yuanyuan, et al.
Publicado: (2021)

Human ACE2 Genetic Polymorphism Affecting SARS-CoV and SARS-CoV-2 Entry into Cells
por: Hattori, Takanari, et al.
Publicado: (2022)

Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing
por: Tomar, Prabhat Pratap Singh, et al.
Publicado: (2021)

ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities
por: Zamorano Cuervo, Natalia, et al.
Publicado: (2020)

MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes
por: Lu, Dongchao, et al.
Publicado: (2020)

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
por: Wang, Qihui, et al.
Publicado: (2020)

TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2
por: Wang, Yinfang, et al.
Publicado: (2021)

SARS-CoV-2 Cellular Entry Is Independent of the ACE2 Cytoplasmic Domain Signaling
por: Karthika, Thankamani, et al.
Publicado: (2021)

Identification of SARS-CoV-2 E Channel Blockers from a Repurposed Drug Library
por: Tomar, Prabhat Pratap Singh, et al.
Publicado: (2021)

Targeting RNA G-quadruplex with repurposed drugs blocks SARS-CoV-2 entry
por: Tong, Qiyu, et al.
Publicado: (2023)

Repurposing 1,2,4-oxadiazoles as SARS-CoV-2 PLpro inhibitors and investigation of their possible viral entry blockade potential
por: Ayoup, Mohammed Salah, et al.
Publicado: (2023)

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
por: Hoffmann, Markus, et al.
Publicado: (2020)

Predicting the Ability of SARS-CoV-2 to Utilize the ACE2 Receptor for Cell Entry in North American Rodents
por: Lund-Andersen, Peik K., et al.
Publicado: (2021)

The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies
por: Albini, Adriana, et al.
Publicado: (2020)

Differential expression in humans of the viral entry receptor ACE2 compared with the short deltaACE2 isoform lacking SARS-CoV-2 binding sites
por: Williams, Thomas L., et al.
Publicado: (2021)

Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2
por: Ge, Shuai, et al.
Publicado: (2021)

“Molecular Masks” for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry
por: Shukla, Satya Prakash, et al.
Publicado: (2021)

Palmitoylethanolamide (PEA) Inhibits SARS-CoV-2 Entry by Interacting with S Protein and ACE-2 Receptor
por: Fonnesu, Rossella, et al.
Publicado: (2022)

Cloaking the ACE2 receptor with salivary cationic proteins inhibits SARS-CoV-2 entry
por: Yoshizato, Katsutoshi, et al.
Publicado: (2022)

Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2
por: Gurung, Arun Bahadur, et al.
Publicado: (2021)

Integrin αvβ1 facilitates ACE2-mediated entry of SARS-CoV-2
por: Cai, Zeqiong, et al.
Publicado: (2023)

Repurposing and computational design of PARP inhibitors as SARS-CoV-2 inhibitors
por: Rampogu, Shailima, et al.
Publicado: (2023)

Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
por: Djomkam, Alexandra Lindsey Zune, et al.
Publicado: (2020)

Expression Pattern of the SARS-CoV-2 Entry Genes ACE2 and TMPRSS2 in the Respiratory Tract
por: Liu, Yichuan, et al.
Publicado: (2020)

Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD
por: Burgueño, Juan F, et al.
Publicado: (2020)

Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2
por: Zhao, Hanjun, et al.
Publicado: (2021)

The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies: comment
por: De Cauwer, Harald
Publicado: (2020)

The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based antihypertensive therapies—reply
por: Albini, Adriana, et al.
Publicado: (2020)

Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein
por: Wang, Lin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_iqhenceki5t13abj4d2f36il9s